Kamada Ltd 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Kamada Ltd in the fourth quarter 2025?
Kamada Ltd achieved a return on average equity (ROE) of 7.72 % in its fourth quarter 2025, this is above KMDA's average return on equity of 7.47%.
Kamada Ltd shareholder's equity over the 12 months ending in its fourth quarter 2025 are valued at $262 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 66 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from to 1777.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Equity Change	3.7 %	3.9 %	3.5 %	0.32 %	-
Y / Y Net Income Change	-6.46 %	37.1 %	66.65 %	67.61 %	-54.03 %
Net Income (TTM) in Millions	20	20	19	16	14
Return On Equity (TTM)	7.72 %	7.89 %	7.41 %	6.31 %	5.69 %
KMDA's Total Ranking	# 1777	#	#	#	#
Equity (TTM) in Millions	269	265	260	252	259
Seq. Equity Change	1.45 %	2.03 %	3.17 %	-2.89 %	1.64 %
Seq. Net Income Change	-32.74 %	-28.2 %	86.07 %	4.1 %	-1.42 %

Back to KMDA Management Effectiveness >> KMDA's 5 Years Annual ROE >> Compare KMDA ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 67
Sector	# 178
Overall	# 1777

Return On Equity Statistics
High	Average	Low
19.84 %	7.47 %	-1.32 %
(Dec 31 2018)		(Dec 31 2022)

News about Kamada Ltd Return on Equity ROE

Kamada Projects Continued Profitable Growth Ahead: 2024 Financial Guidance and Ambitious Plans for 2025,

Kamada Projects Continued Profitable Growth Ahead: 2024 Financial Guidance and Ambitious Plans for 2025 Kamada Projects Continued Profitable Growth Ahead: 2024 Financial Guidance and Ambitious Plans for 2025Kamada Ltd. a biopharmaceutical powerhouse hailing from Rehovot, Israel, has set strong financial expectations for 2024, while revealing an optimistic outlook for 2025. As a key player in the development of medicines targeting rare and serious health conditions, Kamada s financial guidance shines a light on its robust commercial infrastructure and zeal for innovation. 2024 Financial Guidance: Strong Revenue and EBITDA ExpectationsKamada has confirmed its financial guidance for 2024, expecting to generate between $158 million and $162 million in Revenue, alongside an Adjusted EBITDA in the range of $32 million to $35 million. These figures signify a noteworthy year-over-year increase in revenues, estimated at around 13%, and an impressive 19% upswing in Adjusted EBITDA based on the midpoint of this guidance.

KMDA Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	269	259	244	176	177
Y / Y Equity Change	3.7 %	6.33 %	38.63 %	-0.45 %	-1.02 %
Net Income in Millions	20	14	8	-2	-2
Y / Y Net Income Change	39.66 %	74.58 %	-	-	-
Return On Equity	7.51 %	5.57 %	3.39 %	-1.32 %	-1.26 %

Back to KMDA Management Effectiveness >> KMDA's 5 Years Annual ROE >> Compare KMDA ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 7.51 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
KMDA's' Return on Equity at Yahoo Finance
KMDA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for KMDA's Competitors
Subscribers only: Roe for Kamada Ltd 's Suppliers
Subscribers only: Return On Equity for KMDA's Customers

Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector	ROE
Universal Health Services Inc	21.19 %
Inspire Medical Systems inc	21.07 %
Astrazeneca Plc	21.00 %
Haemonetics Corporation	20.80 %
Sbc Medical Group Holdings Incorporated	20.79 %
Lantheus Holdings Inc	20.58 %
Electromed Inc	20.54 %
Teva Pharmaceutical Industries Limited	20.07 %
Harmony Biosciences Holdings inc	19.84 %
Pediatrix Medical Group Inc	19.58 %
United Therapeutics Corporation	19.30 %
Krystal Biotech Inc	18.69 %
Argenx Se	17.64 %
Kewaunee Scientific Corporation	17.52 %
Black Diamond Therapeutics Inc	17.46 %
Insulet Corporation	17.36 %
Ufp Technologies Inc	17.36 %
West Pharmaceutical Services Inc	16.68 %
Neurocrine Biosciences Inc	16.67 %
Ensign Group Inc	16.57 %
Ani Pharmaceuticals Inc	16.48 %
Genmab A	16.47 %
Strata Critical Medical Inc	16.46 %
Intuitive Surgical Inc	16.40 %
Cryoport inc	15.75 %
Lemaitre Vascular Inc	15.58 %
Option Care Health Inc	15.39 %
Sab Biotherapeutics Inc	15.17 %
Corcept Therapeutics Inc	15.11 %
Stryker Corp	15.04 %

Date modified: 2026-09-18T14:10:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.